EZETIMIBE - Generic Drug Details

What are the generic sources for ezetimibe and what is the scope of freedom to operate?

Ezetimibe is the generic ingredient in five branded drugs marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Ohm Labs Inc, Orient Pharma, Rising, Sandoz, Sciegen Pharms, Teva Pharms Usa, Watson Labs Inc, Zydus Pharms, Organon, Althera Pharms, Ani Pharms, Aurobindo Pharma Usa, Dr Reddys Labs Sa, and Torrent, and is included in twenty-eight NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ezetimibe has two hundred and thirty-five patent family members in thirty-eight countries.

There are twenty-four drug master file entries for ezetimibe. Twenty-six suppliers are listed for this compound.

Summary for EZETIMIBE

International Patents:	235
US Patents:	3
Tradenames:	5
Applicants:	22
NDAs:	28
Drug Master File Entries:	24
Finished Product Suppliers / Packagers:	26
Raw Ingredient (Bulk) Api Vendors:	113
Clinical Trials:	386
Drug Prices:	Drug price trends for EZETIMIBE
Drug Sales Revenues:	Drug sales revenues for EZETIMIBE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EZETIMIBE
What excipients (inactive ingredients) are in EZETIMIBE?	EZETIMIBE excipients list
DailyMed Link:	EZETIMIBE at DailyMed

See drug prices for EZETIMIBE

See drug sales revenues for EZETIMIBE

Recent Clinical Trials for EZETIMIBE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Severance Hospital	NA
Sin Gon Kim	NA
Hanmi Pharmaceutical Company Limited	NA

See all EZETIMIBE clinical trials

Pharmacology for EZETIMIBE

Drug Class	Dietary Cholesterol Absorption Inhibitor
Physiological Effect	Decreased Cholesterol Absorption

Medical Subject Heading (MeSH) Categories for EZETIMIBE

Anticholesteremic Agents

Anatomical Therapeutic Chemical (ATC) Classes for EZETIMIBE

C10AX	Other lipid modifying agents
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for EZETIMIBE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZETIA	Tablets	ezetimibe	10 mg	021445	1	2006-10-25

US Patents and Regulatory Information for EZETIMIBE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-003	Mar 23, 2021		DISCN	Yes	No	10,376,470		Y
Teva Pharms Usa	EZETIMIBE	ezetimibe	TABLET;ORAL	078724-001	Jun 12, 2017		DISCN	No	No
Torrent	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	209461-001	Jan 27, 2025		DISCN	No	No
Dr Reddys Labs Sa	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	200909-004	Apr 26, 2017	AB	RX	No	No

Expired US Patents for EZETIMIBE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	5,767,115
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	RE42461*PED
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	5,846,966*PED
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	RE37721*PED

International Patents for EZETIMIBE

Country	Patent Number	Title	Estimated Expiration
Ecuador	SP034703	COMBINACIONES DE INHIBIDOR(ES) DE ABSORCION DE ESTEROL CON AGENTE(S) CARDIOVASCULAR(ES) PARA EL TRATAMINTO DE CONDICIONES VASCULARES
Denmark	1353694
Japan	2009132745	SUGAR-SUBSTITUTED 2-AZETIDINONE USEFUL AS HYPOCHOLESTEROLEMIC AGENT
Norway	326981

Supplementary Protection Certificates for EZETIMIBE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	2003/014	Ireland		PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: 1091/1/1 00040127; FIRST REGISTRATION NO/DATE: EU: DE 54489.00.00 54486.00.00 54488.00.00 54487.00.00 20021017; PAEDIATRIC INVESTIGATION PLAN: P/0061/2012
0720599	92544	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724
0720599	C300172	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402
0720599	300688	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724

Market Dynamics and Financial Trajectory for Ezetimibe

Last updated: February 19, 2026

What Is Ezetimibe’s Current Market Position?

Ezetimibe, sold primarily under the brand Zetia, is a cholesterol absorption inhibitor approved by the FDA in 2002. It is prescribed mainly for hyperlipidemia, often in combination with statins. The drug's global sales reached approximately $1.2 billion in 2022, reflecting stable demand driven by its role in cardiovascular risk management.

What Factors Drive Ezetimibe’s Market Demand?

Clinical Adoption and Prescribing Trends

Ezetimibe’s inclusion in lipid-lowering therapy guidelines sustains its prescription volume. An increase in statin intolerance cases prompts physicians to prescribe ezetimibe as an alternative. Combo formulations with statins (e.g., Vytorin) expand its usage scope, especially for patients requiring aggressive lipid control.

Regulatory and Patent Landscape

Ezetimibe’s patent expiration occurred in 2018 in the U.S., opening the market to generic competition. This led to a drop in prices but increased volume sales due to broader access. Companies like Accords and Mylan introduced generics, capturing significant market share.

Competitive Environment

The primary competitors include PCSK9 inhibitors (e.g., alirocumab, evolocumab), which are more effective but also more costly. The choice between ezetimibe and PCSK9 inhibitors depends on patient risk profiles and insurance coverage.

Market Penetration in Emerging Economies

Growing awareness of cardiovascular health and increasing healthcare infrastructure in Asia, Latin America, and Africa boost ezetimibe’s sales. Price reductions via generics facilitate wider adoption in these regions.

How Do Pricing and Reimbursement Policies Impact Revenue?

Pricing Trends

Post-patent expiry, ezetimibe prices declined by an estimated 70%. In the U.S., average retail costs fell from $150 per month to approximately $45. Insurance reimbursement policies largely cover ezetimibe, maintaining accessibility.

Reimbursement Dynamics

Medicare and private insurers favor cost-effective therapies. Generic ezetimibe is included in formularies, lowering out-of-pocket expenses for patients. Reimbursement policies favor combination therapies that include ezetimibe, maintaining steady prescribing levels.

What Is the Future Financial Trajectory?

Projected Sales Growth

Analysts estimate a compound annual growth rate (CAGR) of 2-3% for ezetimibe’s global sales from 2023 to 2028. The growth projection accounts for increased use in combination therapies, expanding indications, and availability of generics.

Impact of New Indications

Investigations into ezetimibe’s role in nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome could broaden its application. However, approvals remain pending as of 2023, not yet influencing revenues.

Competitive and Market Risks

Introduction of novel lipid-lowering agents with improved efficacy or safety profiles could displace ezetimibe. Patent litigation or regulatory hurdles in emerging markets may suppress growth.

Supply Chain Considerations

The reliance on specific manufacturing facilities and raw material sources may affect availability and pricing stability. Disruptions could impact sales volume and margins.

How Do Regulatory Actions Affect Market Outlook?

Regulatory agencies continually review lipid-lowering therapies. Ezetimibe received a positive assessment from the European Medicines Agency (EMA) in 2021 for its role in combination treatments. Any adverse regulatory action or safety concern could influence its market acceptance.

What Are Key Strategic Opportunities?

Formulation and Delivery Enhancements

Developing fixed-dose combinations with newer agents can expand usage. Reducing pill burden aligns with patient compliance goals.

Market Expansion in Emerging Economies

Partnerships with local distributors and price adjustments can enhance market share. Tailored reimbursement strategies will support broader access.

R&D Investment

Investing in clinical trials for new indications or formulations could foster differentiated offerings. Exploring the drug’s role in non-cardiovascular conditions may unlock additional revenue streams.

Key Financial Data Summary

Metric	2022	Projection (2028)	Notes
Global Sales	$1.2 billion	$1.3–$1.4 billion	Growth driven by volume, offset by price reductions
Patent Status	Expired (2018)	N/A	Induces generic competition
CAGR	N/A	2-3%	Based on analyst estimates
Top Markets	North America, Europe, Asia	Same	Growth in emerging markets

Key Takeaways

• Ezetimibe’s market is stable, supported by its cost-effectiveness and inclusion in guidelines.
• Patent expiration significantly lowered prices but increased access in mature and emerging markets.
• Generics dominate retail markets, pressing margins but expanding volume.
• Competition from high-efficacy drugs like PCSK9 inhibitors influences prescribing patterns.
• Future growth depends on clinical research, formulation innovation, and market expansion strategies.

FAQs

1. How will patent expiration affect ezetimibe’s sales?
Patent expiry in 2018 led to widespread generic availability, reducing prices and margins but increasing volume sales, especially in price-sensitive markets.

2. Are there any new formulations of ezetimibe in development?
Current research focuses on combo pills, fixed-dose formulations, and exploring new indications, but no new formulations have received regulatory approval as of 2023.

3. What are the key competitors to ezetimibe?
PCSK9 inhibitors such as alirocumab and evolocumab offer higher efficacy for high-risk patients but at higher cost.

4. Which regions offer the highest growth potential for ezetimibe?
Emerging economies in Asia and Latin America present opportunities due to expanding healthcare infrastructure and increasing cardiovascular disease awareness.

5. How do reimbursement policies influence ezetimibe’s market?
Insurance coverage and formulary placement favor generic ezetimibe, stabilizing demand despite price pressures.

---

References

[1] Market data sourced from IQVIA, 2022.
[2] FDA regulatory history for ezetimibe.
[3] European Medicines Agency approvals, 2021.
[4] Clinical guideline updates from the American Heart Association, 2022.
[5] Industry analyst projections, GlobalData, 2023.